Allergan came up with a drug that produces eyelashes. The new drug called Latisse has recently received the approval of the Food and Drug Administration (FDA) which is very good news for people suffering from hypotrichosis, a condition in which a person does not have enough eyelashes.

The company said Latisse will be available for prescription in the first quarter of next year.

Latisse will be applied once a day to the eyelid using a disposable applicator. The treatment would improve the length, thickness and color of hairs. In order to maintain the thickness of the eyelashes continued use is necessary. If the Latisse treatment is stopped, the eyelashes will return to their previous appearance as new eyelashes grow in.

As for the side effects, eye redness and itchiness, a darkening of the eyelid skin and a permanent darkening of the whites of the eyes could occur.

The active ingredient of Latisse is bimatroprost, the same ingredient used by Allergan in its glaucoma treatment Lumigan. In fact, a glaucoma specialist first discovered the eyelash effect.

"Latisse users can expect to experience longer, fuller, and darker eyelashes in as little as eight weeks, with full results in 16 weeks," the drug producer stated. The company added that Latisse is the “first and only” science-based treatment approved by the FDA to enhance eyelash prominence.

Allergan estimated that the sales of Latisse, which is expected to cost about $120, could go as high as 500 million U.S. dollars a year.